You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
Prototypical and defining agonist for the AMPA subgroup of ionotropic glutamate receptors.
|Storage||Store at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
|water||1.86||10 with gentle warming|
Preparing Stock Solutions
The following data is based on the product molecular weight 186.17. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|0.1 mM||53.71 mL||268.57 mL||537.14 mL|
|0.5 mM||10.74 mL||53.71 mL||107.43 mL|
|1 mM||5.37 mL||26.86 mL||53.71 mL|
|5 mM||1.07 mL||5.37 mL||10.74 mL|
References are publications that support the biological activity of the product.
Honore et al (1982) The binding of 3H-AMPA, a structural analogue of glutamic acid, to rat brain membranes. J.Neurochem. 38 173 PMID: 6125564
Krogsgaard-Larsen et al (1980) New class of glutamate agonist structurally related to ibotenic acid. Nature 284 64 PMID: 6101908
If you know of a relevant reference for (RS)-AMPA, please let us know.
View Related Products by Product Action
Keywords: (RS)-AMPA, (RS)-AMPA supplier, Selective, AMPA, agonists, Glutamate, Receptors, iGluR, Ionotropic, 74341-63-2, 0169, Tocris Bioscience
19 Citations for (RS)-AMPA
Citations are publications that use Tocris products. Selected citations for (RS)-AMPA include:
Rojas et al (2013) Activation of group I metabotropic glutamate receptors potentiates heteromeric kainate receptors. Mol Pharmacol 83 106 PMID: 23066089
Guntupalli et al (2017) GluA1 subunit ubiquitination mediates amyloid-β-induced loss of surface α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors. J Biol Chem 292 8186 PMID: 28377502
Angelantonio et al (2015) Basal adenosine modulates the functional properties of AMPA receptors in mouse hippocampal neurons through the activation of A1R A2AR and A3R. Front Cell Neurosci 9 409 PMID: 26528137
Nygaard et al (2015) Melanoma brain colonization involves the emergence of a brain-adaptive phenotype. Oncoscience 1 82 PMID: 25593989
Ye et al (2019) KA metabolite (2R,6R)-hydroxynorKA enhances aggression via periaqueductal gray glutamatergic transmission. Neuropharmacology 157 PMID: 31207251
Netzahualcoyotzi and Tapia (2015) Degeneration of spinal motor neurons by chronic AMPA-induced excitotoxicity in vivo and protection by energy substrates. Acta Neuropathol Commun 3 27 PMID: 25968178
Falgairolle and O'Donovan (2015) Pharmacological Investigation of Fluoro-Gold Entry into Spinal Neurons. PLoS One 10 e0131430 PMID: 26102354
Chanda et al (2014) Generation of induced neuronal cells by the single reprogramming factor ASCL1. Stem Cell Reports 3 282 PMID: 25254342
Gangadharan et al (2011) Peripheral calcium-permeable AMPA receptors regulate chronic inflammatory pain in mice. J Clin Invest 121 1608 PMID: 21383497
Schenk et al (2003) Regulated delivery of AMPA receptor subunits to the presynaptic membrane. EMBO J 22 558 PMID: 12554656
Chen et al (2002) Development of a human neuronal cell model for human immunodeficiency virus (HIV)-infected macrophage-induced neurotoxicity: apoptosis induced by HIV type 1 primary isolates and evidence for involvement of the Bcl-2/Bcl-xL-sensitive intrinsic apoptosis pa J Virol 76 9407 PMID: 12186923
Suyama et al (2017) Plasticity of calcium-permeable AMPA glutamate receptors in Pro-opiomelanocortin neurons. Elife 6 PMID: 28762946
Fedele and Raiteri (1996) Desensitization of AMPA receptors and AMPA-NMDA receptor interaction: an in vivo cyclic GMP microdialysis study in rat cerebellum. Br J Pharmacol 117 1133 PMID: 8882607
Fedele et al (1996) In vivo microdialysis study of a specific inhibitor of soluble guanylyl cyclase on the glutamate receptor/nitric oxide/cyclic GMP pathway. Br J Pharmacol 119 590 PMID: 8894183
Biou et al (2008) Endocytosis and recycling of AMPA receptors lacking GluR2/3. Proc Natl Acad Sci U S A 105 1038 PMID: 18195348
Fakira et al (2012) Purkinje cell dysfunction and delayed death in plasma membrane calcium ATPase 2-heterozygous mice. Mol Cell Neurosci 51 22 PMID: 22789621
Mahajan et al (2011) Exposure of neurons to excitotoxic levels of glutamate induces cleavage of the RNA editing enzyme, adenosine deaminase acting on RNA 2, and loss of GLUR2 editing. Neuroscience 189 305 PMID: 21620933
Chou et al (2018) (2R,6R)-hydroxynorKA rescues chronic stress-induced depression-like behavior through its actions in the midbrain periaqueductal gray. Neuropharmacology 139 1 PMID: 29953886
Maier et al (2010) Sustained glutamate receptor activation down-regulates GABAB receptors by shifting the balance from recycling to lysosomal degradation. J Biol Chem 285 35606 PMID: 20826795
Do you know of a great paper that uses (RS)-AMPA from Tocris? Please let us know.
Reviews for (RS)-AMPA
Average Rating: 5 (Based on 1 Review.)
Have you used (RS)-AMPA?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Used to measure calcium influx in motor neurons upon AMPA receptor stimulation. 50 micromolar AMPA was added to the bath during live imaging of motor neurons loaded with calcium indicator FURA-2 AM
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Alzheimer's disease (AD) is a degenerative brain disease and the most common cause of dementia, affecting approximately 47 million people worldwide. Updated in 2015, this poster summarizes the structural and functional changes observed in the progression of this neurodegenerative disease, as well as classic AD drug targets.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Epilepsy is a brain disease that affects 60 million people globally. More than 20 anti-seizure drugs are currently available, but these do not address the underlying causes of the condition. This poster summarizes current knowledge about the development of the condition and highlights some approaches that have disease-modifying effects in proof-of-concept studies.
Learning & Memory Poster
Recognition memory enables us to make judgements about whether or not we have encountered a particular stimulus before. This poster outlines the cellular mechanisms underlying recognition memory and its links to long-term depression, as well as the use of pharmacological intervention to assess the role of neurotransmitters in recognition memory.
Peripheral sensitization is the reduction in the threshold of excitability of sensory neurons that results in an augmented response to a given external stimulus. This poster outlines the excitatory and inhibitory signaling pathways involved in modulation of peripheral sensitization. The role of ion channels, GPCRs, neurotrophins, and cytokines in sensory neurons are also described.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.
Schizophrenia is a debilitating psychiatric disorder that affects 1% of the worldwide population. This poster describes the neurobiology of Schizophrenia, as well as highlighting the genetic and environmental factors that play a fundamental role in the etiology of the disease. The current and emerging drug targets are also discussed.